Related Experiment Video

Updated: Jul 7, 2026

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo
12:42

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo

Published on: January 7, 2019

Modeling of cancer virotherapy with recombinant measles viruses

Zeljko Bajzer1, Thomas Carr, Kresimir Josić

  • 1Biomathematics Resource and Department of Biochemistry and Molecular Biology, Mayo Clinic College of Medicine, Guggenheim 1611b, Rochester, MN 55905, USA. bajzer@mayo.edu

Journal of Theoretical Biology
|March 5, 2008
PubMed

Insights

The Edmonston measles virus effectively targets tumors by causing infected cells to fuse and die. Mathematical modeling of tumor-virus interactions predicts conditions for successful therapy and tumor eradication.

Area of Science:

  • Oncolytic virotherapy
  • Mathematical modeling of infectious diseases
  • Tumor immunology

Background:

  • The Edmonston vaccine strain of measles virus demonstrates significant anti-tumor properties.
  • Measles virus infection induces tumor cell fusion (syncytia) leading to cell death.
  • Viral proteins expressed by infected cells mediate syncytia formation and viral spread.

Purpose of the Study:

  • To develop a mathematical model of tumor and measles virus interactions.
  • To analyze the stability of tumor states under virotherapy.
  • To identify conditions favoring tumor eradication using measles virus.

Main Methods:

  • Mathematical modeling incorporating free virus population dynamics.
  • Parameter estimation by fitting the model to experimental data.
  • Numerical simulations to explore therapy outcomes and stability analysis.

Main Results:

  • The model predicts equilibrium states for tumor eradication, failure, and partial reduction.
  • Numerical simulations explore conditions for successful oncolytic virotherapy.
  • Damped and stable oscillations in tumor-virus dynamics were observed, organized by a Hopf bifurcation.

Conclusions:

  • The Edmonston measles virus shows promise as an oncolytic agent.
  • Mathematical modeling provides insights into the dynamics of tumor-virus interactions.
  • The study identifies parameters influencing the success of measles virus-based tumor therapy.

More Related Videos

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine09:15

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Published on: February 24, 2023

Related Concept Videos

Rous Sarcoma Virus (RSV) and Cancer01:03

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand  RNA genome. Its genome consists of four main open...
Rous Sarcoma Virus (RSV) and Cancer01:03

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand  RNA genome. Its genome consists of four main open...
Mechanisms of Retrovirus-induced Cancers01:51

Mechanisms of Retrovirus-induced Cancers

Retroviruses are RNA viruses that have been shown to cause cancers in diverse species, including chickens, mice, cats, and monkeys. The RNA genomes of these viruses are first reverse-transcribed into single and then double-stranded DNA (dsDNA) copies. This dsDNA called proviral DNA then integrates into the host genome. Subsequently, the host cell transcribes the proviral DNA in concert with the chromosomal DNA. This leads to the production of viral RNA and proteins that assemble at the host...
Mechanisms of Retrovirus-induced Cancers01:51

Mechanisms of Retrovirus-induced Cancers

Retroviruses are RNA viruses that have been shown to cause cancers in diverse species, including chickens, mice, cats, and monkeys. The RNA genomes of these viruses are first reverse-transcribed into single and then double-stranded DNA (dsDNA) copies. This dsDNA called proviral DNA then integrates into the host genome. Subsequently, the host cell transcribes the proviral DNA in concert with the chromosomal DNA. This leads to the production of viral RNA and proteins that assemble at the host...
Cancer Vaccines01:30

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.